Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ESMO

Charles Morris appointed chief development officer at ImmunoGen

Previously worked in oncology for Allos, Cephalon and AstraZeneca

Eisai: Bucking the trend with R&D growth

PME’s emerging companies series continues with a firm that’s committed to research as it expands its commercial position

- PMLiVE

Astellas seeks FDA approval for personalised Tarceva in lung cancer

Application supported by Roche's EGFR companion diagnostic test

- PMLiVE

Roche’s Avastin cuts progression of aggressive brain cancer

Supports potential new indication for oncology medicine

Sanofi reception

Sanofi’s Lyxumia and Zaltrap backed for European approval

Company on course to expand its diabetes and cancer portfolio

Roche, social media and patients – part 2

Patient groups talk about their use of social media and the challenges they face

- PMLiVE

WHO launches framework to monitor non-communicable diseases

Will measure success of efforts to reduce rates of cancer, diabetes, lung conditions and heart disease

- PMLiVE

New hope for castration-resistant prostate cancer

An unprecedented number of therapies have reached late-stage clinical trials or been approved over recent years targeting this disease with an unmet medical need

- PMLiVE

NICE rejects Pierre Fabre’s bladder cancer drug Javlor

Says drug received final draft 'no' because pharma company failed to prove efficacy

- PMLiVE

Good practice in cancer care recognised at UK awards

Sir Mike Richards honoured with lifetime achievement award at QiC Excellence in Oncology 2012

- PMLiVE

Roche’s Avastin cleared in EU for recurrent ovarian cancer

Becomes first biologic to win approval for platinum-sensitive ovarian cancer

- PMLiVE

Menarini signs €800m cancer antibody deal

Will work with Oxford BioTherapeutics on antibody-drug conjugates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links